• Phase 3 trial for chronic wound treatment TR987 progressing with 64 patients randomized to date
• TR Pro+ product sales reached 9,000 units in Q1 2026, with major production run planned for Q2
• Company expects to receive R&D tax rebate of ~$2 million for FY2025

Tissue Repair Ltd (ASX:TRP) released its Appendix 4C Quarterly Cashflow Report for the period ended 31 March 2026. Key highlights include:TR987 for chronic wound treatment:- Phase 3 trial recruitment has accelerated, with 64 patients randomized to date and a further 11 in screening. The company expects to reach ~70 patient randomizations in the near term.- 25 sites are currently active, with 6 more in the process of being activated. The company will pause at 30 sites.- The focus is on reaching ~100 patient randomizations by September 2026 to trigger an interim analysis.TR Pro+ for aesthetic and medical procedures:- Sales reached 9,000 units in Q1 2026, including 7,524 tubes sold to Advanced Cosmeceuticals and 1,513 medical sales.- A major production run of ~78,000 tubes across all SKUs is scheduled for May-June 2026, ahead of a formal product launch.- Advanced Cosmeceuticals expects to achieve ~5,000 monthly tube sales once all SKUs are available.Financials:- The company had $6.657 million in cash at 31 March 2026.- Net operating cash outflows were $1.684 million, primarily for R&D, manufacturing, and operations.- An R&D tax rebate of ~$2 million for FY2025 has been lodged, with the FY2026 rebate expected to provide additional cash inflows.- Based on current expenditure, the company has an estimated 4 quarters of funding runway.

The company's core near-term focus is to achieve the interim analysis target of ~100 patient randomizations in the TR987 Phase 3 trial by June/July 2026. Additionally, the company is progressing the 510(k) and CE mark regulatory pathway for its TR Pro+ product, which may provide an alternative to the drug development pathway.